{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T01:11:21Z","timestamp":1760058681672,"version":"build-2065373602"},"reference-count":70,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T00:00:00Z","timestamp":1745193600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002713","name":"Deanship of Scientific Research at Imam Mohammad Ibn Saud Islamic University (IMSIU)","doi-asserted-by":"publisher","award":["IMSIU-DDRSP2501"],"award-info":[{"award-number":["IMSIU-DDRSP2501"]}],"id":[{"id":"10.13039\/501100002713","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Background\u00a0and objectives: Hypertension remains a leading global cause of cardiovascular morbidity and mortality, with suboptimal blood pressure (BP) control despite available treatments. Monotherapy often fails to achieve target BP, necessitating combination therapies. Quadruple low-dose combination therapy (quadpill) has emerged as a potential strategy to enhance efficacy while minimizing side effects. This systematic review evaluates the effectiveness and safety of quadpill therapy compared to standard monotherapy and dual therapy. Methods: A systematic search was conducted in PubMed, Web of Science, and Scopus from inception till January 2025 for randomized controlled trials (RCTs) investigating quadruple therapy in hypertensive patients. Studies comparing quadpill therapy with monotherapy, dual therapy, or placebo were included. Data on BP reduction, achievement of target BP, and adverse events were extracted and analyzed. The Cochrane Risk of Bias tool (RoB-2) was used to assess study quality. Results: Five RCTs were included in the current systematic review. Quadpill therapy resulted in greater reductions in systolic BP (SBP and diastolic BP (DBP) compared to monotherapy and dual therapy across all time points. The proportion of patients achieving target BP (&lt;140\/90 mmHg) was significantly higher in the quadpill group. The safety profile was favorable, with adverse event rates comparable to those in monotherapy and dual therapy groups. Notable adverse effects included mild dizziness, edema, and biochemical alterations (elevated fasting glucose and uric acid levels), but these did not lead to significant treatment discontinuation. Conclusions: Quadruple low-dose combination therapy is a promising approach for improving BP control while maintaining a favorable safety profile. Early initiation of quadpill therapy could mitigate treatment inertia and improve long-term cardiovascular outcomes.<\/jats:p>","DOI":"10.3390\/medicina61040764","type":"journal-article","created":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T04:57:11Z","timestamp":1745211431000},"page":"764","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Use of Quadruple Therapy in the Management of Hypertension: A Systematic Review of Randomized Controlled Trials"],"prefix":"10.3390","volume":"61","author":[{"given":"Khalid A.","family":"Alnemer","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Faculty of Medicine, Imam Mohammad Ibn Saud Islamic University (IMSIU), Riyadh 13317, Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,4,21]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1097\/HJH.0000000000002453","article-title":"2020 International Society of Hypertension global hypertension practice guidelines","volume":"38","author":"Unger","year":"2020","journal-title":"J. Hypertens."},{"key":"ref_2","first-page":"182","article-title":"2018 Chinese Guidelines for Prevention and Treatment of Hypertension-A report of the Revision Committee of Chinese Guidelines for Prevention and Treatment of Hypertension","volume":"16","author":"Liu","year":"2019","journal-title":"J. Geriatr. Cardiol."},{"key":"ref_3","unstructured":"GBD 2019 Risk Factors Collaborators (2020). Global burden of 87 risk factors in 204 countries and territories, 1990\u20132019: A systematic analysis for the Global Burden of Disease Study 2019. Lancet, 396, 1223\u20131249. (In English)."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2549","DOI":"10.1016\/S0140-6736(17)32478-9","article-title":"Prevalence, awareness, treatment, and control of hypertension in China: Data from 1\u00b77 million adults in a population-based screening study (China PEACE Million Persons Project)","volume":"390","author":"Lu","year":"2017","journal-title":"Lancet"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"3912","DOI":"10.1093\/eurheartj\/ehae178","article-title":"2024 ESC Guidelines for the management of elevated blood pressure and hypertension","volume":"45","author":"McEvoy","year":"2024","journal-title":"Eur. Heart J."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.tcm.2019.05.003","article-title":"Blood pressure and the new ACC\/AHA hypertension guidelines","volume":"30","author":"Flack","year":"2020","journal-title":"Trends Cardiovasc. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S0140-6736(05)17741-1","article-title":"Global burden of hypertension: Analysis of worldwide data","volume":"365","author":"Kearney","year":"2005","journal-title":"Lancet"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1016\/S0140-6736(98)07614-4","article-title":"Optimisation of antihypertensive treatment by crossover rotation of four major classes","volume":"353","author":"Dickerson","year":"1999","journal-title":"Lancet"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1001\/jama.2013.184182","article-title":"Prevalence, awareness, treatment, and control of hypertension in rural and urban communities in high-, middle-, and low-income countries","volume":"310","author":"Chow","year":"2013","journal-title":"JAMA"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.amjmed.2008.09.038","article-title":"Combination therapy versus monotherapy in reducing blood pressure: Meta-analysis on 11,000 participants from 42 trials","volume":"122","author":"Wald","year":"2009","journal-title":"Am. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S0140-6736(15)00805-3","article-title":"Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: Updated systematic review and meta-analysis","volume":"387","author":"Xie","year":"2016","journal-title":"Lancet"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"SPRINT Research Group, Wright, J.T., Williamson, J.D., Whelton, P.K., Snyder, J.K., Sink, K.M., Rocco, M.V., Reboussin, D.M., Rahman, M., and Oparil, S. (2015). A Randomized Trial of Intensive versus Standard Blood-Pressure Control. N. Engl. J. Med., 373, 2103\u20132116. (In English).","DOI":"10.1056\/NEJMoa1511939"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1136\/bmj.328.7440.634","article-title":"British Hypertension Society guidelines for hypertension management 2004 (BHS-IV): Summary","volume":"328","author":"Williams","year":"2004","journal-title":"BMJ"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1161\/01.HYP.0000107251.49515.c2","article-title":"Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure","volume":"42","author":"Chobanian","year":"2003","journal-title":"Hypertension"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1136\/bmj.326.7404.1427","article-title":"Value of low dose combination treatment with blood pressure lowering drugs: Analysis of 354 randomised trials","volume":"326","author":"Law","year":"2003","journal-title":"BMJ"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/S0140-6736(17)30260-X","article-title":"Quarter-dose quadruple combination therapy for initial treatment of hypertension: Placebo-controlled, crossover, randomised trial and systematic review","volume":"389","author":"Chow","year":"2017","journal-title":"Lancet"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1001\/archinte.165.10.1147","article-title":"Predictors of adherence with antihypertensive and lipid-lowering therapy","volume":"165","author":"Chapman","year":"2005","journal-title":"Arch. Intern. Med."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Cao, P., Toyabe, S., Abe, T., and Akazawa, K. (2006). Profit and loss analysis for an intensive care unit (ICU) in Japan: A tool for strategic management. BMC Health Serv. Res., 6, (In English).","DOI":"10.1186\/1472-6963-6-1"},{"key":"ref_19","first-page":"2","article-title":"A retrospective study of persistence with single-pill combination therapy vs. concurrent two-pill therapy in patients with hypertension","volume":"9","author":"Dezii","year":"2000","journal-title":"Manag. Care"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1161\/HYPERTENSIONAHA.117.09202","article-title":"Efficacy and Safety of Quarter-Dose Blood Pressure-Lowering Agents: A Systematic Review and Meta-Analysis of Randomized Controlled Trials","volume":"70","author":"Bennett","year":"2017","journal-title":"Hypertension"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1161\/01.HYP.0000254479.66645.a3","article-title":"Low-dose quadruple antihypertensive combination: More efficacious than individual agents\u2014A preliminary report","volume":"49","author":"Mahmud","year":"2007","journal-title":"Hypertension"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Wald, D.S., Morris, J.K., and Wald, N.J. (2012). Randomized Polypill crossover trial in people aged 50 and over. PLoS ONE, 7, (In English).","DOI":"10.1371\/journal.pone.0041297"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"b2535","DOI":"10.1136\/bmj.b2535","article-title":"Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement","volume":"339","author":"Moher","year":"2009","journal-title":"BMJ"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1080\/1941126X.2018.1444339","article-title":"Rayyan for systematic reviews","volume":"30","author":"Johnson","year":"2018","journal-title":"J. Electron. Resour. Librariansh."},{"key":"ref_25","unstructured":"(2025, April 17). RoB 2: A Revised Cochrane Risk-of-Bias Tool for Randomized Trials|Cochrane Bias. Available online: https:\/\/methods.cochrane.org\/bias\/resources\/rob-2-revised-cochrane-risk-bias-tool-randomized-trials."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1111\/jch.14207","article-title":"A double-blind, placebo-controlled trial on the antihypertensive treatment effect of a quadruple single-pill combination","volume":"23","author":"Hu","year":"2021","journal-title":"J. Clin. Hypertens. (Greenwich)"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ahj.2023.05.019","article-title":"Initial treatment with a single capsule containing half-dose quadruple therapy vs standard-dose dual therapy in hypertensive patients (QUADUAL): Study protocol for a randomized, blinded, crossover trial","volume":"264","author":"Zhao","year":"2023","journal-title":"Am. Heart J."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/S0140-6736(21)01922-X","article-title":"Initial treatment with a single pill containing quadruple combination of quarter doses of blood pressure medicines versus standard dose monotherapy in patients with hypertension (QUARTET): A phase 3, randomised, double-blind, active-controlled trial","volume":"398","author":"Chow","year":"2021","journal-title":"Lancet"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1097\/HJH.0000000000003480","article-title":"2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA)","volume":"41","author":"Mancia","year":"2023","journal-title":"J. Hypertens."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1161\/HYP.0000000000000066","article-title":"2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"71","author":"Whelton","year":"2018","journal-title":"Hypertension"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1093\/eurheartj\/ehy339","article-title":"2018 ESC\/ESH Guidelines for the management of arterial hypertension","volume":"39","author":"Williams","year":"2018","journal-title":"Eur. Heart J."},{"key":"ref_32","unstructured":"Update, E.H.G. (2024, June 24). Bringing Us Closer Together Across the Pond-American College of Cardiology [Internet]. 2023th ed. Available online: https:\/\/www.acc.org\/Latest-in-Cardiology\/Articles\/2024\/02\/05\/11\/43\/2023-ESH-Hypertension-Guideline-Update."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1016\/S0140-6736(21)00590-0","article-title":"Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: An individual participant-level data meta-analysis","volume":"397","author":"Rahimi","year":"2021","journal-title":"Lancet"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1161\/CIRCULATIONAHA.117.032582","article-title":"Potential US Population Impact of the 2017 ACC\/AHA High Blood Pressure Guideline","volume":"137","author":"Muntner","year":"2018","journal-title":"Circulation"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1097\/HJH.0000000000001994","article-title":"Effects of blood pressure lowering on cardiovascular events, in the context of regression to the mean: A systematic review of randomized trials","volume":"37","author":"Salam","year":"2019","journal-title":"J. Hypertens."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"SPRINT Research Group, Lewis, C.E., Fine, L.J., Beddhu, S., Cheung, A.K., Cushman, W.C., Cutler, J.A., Evans, G.W., Johnson, K.C., and Kitzman, D.W. (2021). Final Report of a Trial of Intensive versus Standard Blood-Pressure Control. N. Engl. J. Med., 384, 1921\u20131930. (In English).","DOI":"10.1056\/NEJMoa1901281"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1093\/eurheartj\/ehr177","article-title":"Hypertension management 2011: Optimal combination therapy","volume":"32","author":"Sever","year":"2011","journal-title":"Eur. Heart J."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.ahj.2011.05.010","article-title":"Combination therapy as initial treatment for newly diagnosed hypertension","volume":"162","author":"Byrd","year":"2011","journal-title":"Am. Heart J."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1161\/HYPERTENSIONAHA.108.123455","article-title":"A simplified approach to the treatment of uncomplicated hypertension: A cluster randomized, controlled trial","volume":"53","author":"Feldman","year":"2009","journal-title":"Hypertension"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.ahj.2013.10.020","article-title":"TRIple pill vs Usual care Management for Patients with mild-to-moderate Hypertension (TRIUMPH): Study protocol","volume":"167","author":"Salam","year":"2014","journal-title":"Am. Heart J."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.ijcard.2015.12.015","article-title":"Effectiveness of fixed dose combination medication (\u2018polypills\u2019) compared with usual care in patients with cardiovascular disease or at high risk: A prospective, individual patient data meta-analysis of 3140 patients in six countries","volume":"205","author":"Webster","year":"2016","journal-title":"Int. J. Cardiol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1016\/S0140-6736(04)16456-8","article-title":"Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial","volume":"363","author":"Weber","year":"2004","journal-title":"Lancet"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1161\/HYPERTENSIONAHA.112.201566","article-title":"Initial combination therapy reduces the risk of cardiovascular events in hypertensive patients: A matched cohort study","volume":"61","author":"Gradman","year":"2013","journal-title":"Hypertension"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1161\/HYPERTENSIONAHA.111.177592","article-title":"Cardiovascular protection by initial and subsequent combination of antihypertensive drugs in daily life practice","volume":"58","author":"Corrao","year":"2011","journal-title":"Hypertension"},{"key":"ref_45","first-page":"881","article-title":"Benefit of initial dual-therapy on stroke prevention in Chinese hypertensive patients: A real world cohort study","volume":"7","author":"Yu","year":"2015","journal-title":"J. Thorac. Dis."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Gu, D., He, J., Coxson, P.G., Rasmussen, P.W., Huang, C., Thanataveerat, A., Tzong, K.Y., Xiong, J., Wang, M., and Zhao, D. (2015). The Cost-Effectiveness of Low-Cost Essential Antihypertensive Medicines for Hypertension Control in China: A Modelling Study. PLoS Med., 12, (In English).","DOI":"10.1371\/journal.pmed.1001860"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1161\/HYPERTENSIONAHA.120.15462","article-title":"Treatment Patterns and Blood Pressure Control With Initiation of Combination Versus Monotherapy Antihypertensive Regimens","volume":"77","author":"An","year":"2021","journal-title":"Hypertension"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1097\/HJH.0000000000001181","article-title":"Blood pressure control in hypertension. Pros and cons of available treatment strategies","volume":"35","author":"Mancia","year":"2017","journal-title":"J. Hypertens."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1097\/HJH.0000000000000409","article-title":"Comparison of single-pill strategies first line in hypertension: Perindopril\/amlodipine versus valsartan\/amlodipine","volume":"33","author":"Mancia","year":"2015","journal-title":"J. Hypertens."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.jash.2010.03.001","article-title":"Combination therapy in hypertension","volume":"4","author":"Gradman","year":"2010","journal-title":"J. Am. Soc. Hypertens."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/j.amjhyper.2007.02.017","article-title":"Time to achieve blood-pressure goal: Influence of dose of valsartan monotherapy and valsartan and hydrochlorothiazide combination therapy","volume":"20","author":"Weir","year":"2007","journal-title":"Am. J. Hypertens."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/S0140-6736(10)62003-X","article-title":"Aliskiren and the calcium channel blocker amlodipine combination as an initial treatment strategy for hypertension control (ACCELERATE): A randomised, parallel-group trial","volume":"377","author":"Brown","year":"2011","journal-title":"Lancet"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1001\/jama.2018.10359","article-title":"Fixed Low-Dose Triple Combination Antihypertensive Medication vs Usual Care for Blood Pressure Control in Patients With Mild to Moderate Hypertension in Sri Lanka: A Randomized Clinical Trial","volume":"320","author":"Webster","year":"2018","journal-title":"Jama"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"5735","DOI":"10.2147\/DDDT.S286586","article-title":"Low-Dose Triple Antihypertensive Combination Therapy in Patients with Hypertension: A Randomized, Double-Blind, Phase II Study","volume":"14","author":"Hong","year":"2020","journal-title":"Drug Des. Devel Ther."},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Zhao, X., Liu, T., Yang, Q., Yang, G., Li, X., Tang, X., Li, J., Liang, Z., Li, A., and Zeng, L. (2025). Initial treatment with a single capsule containing half-dose quadruple therapy vs standard-dose dual therapy in hypertensive patients (QUADUAL): A randomized, blinded, crossover trial. BMC Med., 23, (In English).","DOI":"10.1186\/s12916-025-03892-8"},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Chung, S.-C., Pujades-Rodriguez, M., Duyx, B., Denaxas, S.C., Pasea, L., Hingorani, A., Timmis, A., Williams, B., and Hemingway, H. (2018). Time spent at blood pressure target and the risk of death and cardiovascular diseases. PLoS ONE, 13, (In English).","DOI":"10.1371\/journal.pone.0202359"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"e007131","DOI":"10.1161\/JAHA.117.007131","article-title":"Time in Therapeutic Range, as a Determinant of All-Cause Mortality in Patients with Hypertension","volume":"6","author":"Doumas","year":"2017","journal-title":"J. Am. Heart Assoc."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1016\/j.jacc.2021.01.014","article-title":"Systolic Blood Pressure Time in Target Range and Cardiovascular Outcomes in Patients With Hypertension","volume":"77","author":"Fatani","year":"2021","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/S0140-6736(19)31293-0","article-title":"Blood pressure control: A challenge to global health systems","volume":"394","author":"Chow","year":"2019","journal-title":"Lancet"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1111\/jch.13655","article-title":"Scaling up effective treatment of hypertension\u2014A pathfinder for universal health coverage","volume":"21","author":"Frieden","year":"2019","journal-title":"J. Clin. Hypertens."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1161\/CIRCULATIONAHA.115.018912","article-title":"Global Disparities of Hypertension Prevalence and Control: A Systematic Analysis of Population-Based Studies From 90 Countries","volume":"134","author":"Mills","year":"2016","journal-title":"Circulation"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/S0140-6736(19)30955-9","article-title":"The state of hypertension care in 44 low-income and middle-income countries: A cross-sectional study of nationally representative individual-level data from 1\u00b71 million adults","volume":"394","author":"Geldsetzer","year":"2019","journal-title":"Lancet"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"e411","DOI":"10.1016\/S2468-2667(17)30141-X","article-title":"Availability and affordability of blood pressure-lowering medicines and the effect on blood pressure control in high-income, middle-income, and low-income countries: An analysis of the PURE study data","volume":"2","author":"Attaei","year":"2017","journal-title":"Lancet Public Health"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1056\/NEJM200003303421301","article-title":"Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis Risk in Communities Study","volume":"342","author":"Gress","year":"2000","journal-title":"N. Engl. J. Med."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1007\/s11606-020-05731-3","article-title":"Thiazide Diuretic-Induced Change in Fasting Plasma Glucose: A Meta-analysis of Randomized Clinical Trials","volume":"35","author":"Hall","year":"2020","journal-title":"J. Gen. Intern. Med."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1038\/s41440-019-0356-x","article-title":"Genetic factors associated with elevation of uric acid after treatment with thiazide-like diuretic in patients with essential hypertension","volume":"43","author":"Ohta","year":"2020","journal-title":"Hypertens. Res."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/1475-2840-10-45","article-title":"Adverse effect profile of trichlormethiazide: A retrospective observational study","volume":"10","author":"Takahashi","year":"2011","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1001\/jama.2022.19590","article-title":"Treatment of Hypertension: A Review","volume":"328","author":"Carey","year":"2022","journal-title":"JAMA"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1038\/s41371-022-00704-x","article-title":"Hypokalaemia associated with hydrochlorothiazide used in the treatment of hypertension in NHANES 1999\u20132018","volume":"37","author":"Lin","year":"2023","journal-title":"J. Hum. Hypertens."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/61\/4\/764\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:18:37Z","timestamp":1760030317000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/61\/4\/764"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,21]]},"references-count":70,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,4]]}},"alternative-id":["medicina61040764"],"URL":"https:\/\/doi.org\/10.3390\/medicina61040764","relation":{},"ISSN":["1648-9144"],"issn-type":[{"type":"electronic","value":"1648-9144"}],"subject":[],"published":{"date-parts":[[2025,4,21]]}}}